tobramycin

Summary

Summary: An aminoglycoside, broad-spectrum antibiotic produced by Streptomyces tenebrarius. It is effective against gram-negative bacteria, especially the PSEUDOMONAS species. It is a 10% component of the antibiotic complex, NEBRAMYCIN, produced by the same species.

Top Publications

  1. pmc Contributions of antibiotic penetration, oxygen limitation, and low metabolic activity to tolerance of Pseudomonas aeruginosa biofilms to ciprofloxacin and tobramycin
    Marshall C Walters
    Center for Biofilm Engineering, Department of Chemical Engineering, Montana State University Bozeman, Bozeman, Montana 59717 3980, USA
    Antimicrob Agents Chemother 47:317-23. 2003
  2. ncbi Synergistic antibacterial efficacy of early combination treatment with tobramycin and quorum-sensing inhibitors against Pseudomonas aeruginosa in an intraperitoneal foreign-body infection mouse model
    Louise D Christensen
    Department of International Health, Immunology and Microbiology, Faculty of Health Sciences, University of Copenhagen, DK 2200 Copenhagen, Denmark
    J Antimicrob Chemother 67:1198-206. 2012
  3. pmc Fosfomycin/tobramycin for inhalation in patients with cystic fibrosis with pseudomonas airway infection
    Bruce C Trapnell
    Cincinnati Children s Hospital Medical Center, OH 45229, USA
    Am J Respir Crit Care Med 185:171-8. 2012
  4. ncbi Aminoglycoside antibiotics induce bacterial biofilm formation
    Lucas R Hoffman
    Department of Pediatrics, University of Washington, Seattle, Washington 98195, USA
    Nature 436:1171-5. 2005
  5. ncbi Pseudomonas aeruginosa tolerance to tobramycin, hydrogen peroxide and polymorphonuclear leukocytes is quorum-sensing dependent
    Thomas Bjarnsholt
    Centre for Biomedical Microbiology, BioCentrum, Technical University of Denmark, DK 2800 Lyngby, Denmark
    Microbiology 151:373-83. 2005
  6. pmc Tobramycin and FDA-approved iron chelators eliminate Pseudomonas aeruginosa biofilms on cystic fibrosis cells
    Sophie Moreau-Marquis
    Department of Physiology, Dartmouth Medical School, Hanover, NH 03755, USA
    Am J Respir Cell Mol Biol 41:305-13. 2009
  7. ncbi Incidence and risk factors for multiple antibiotic-resistant Pseudomonas aeruginosa in cystic fibrosis
    Christian A Merlo
    The Johns Hopkins University School of Medicine, 1830 E Monument St Fifth Floor, Baltimore, MD 21205, USA
    Chest 132:562-8. 2007
  8. pmc Resistance emergence mechanism and mechanism of resistance suppression by tobramycin for cefepime for Pseudomonas aeruginosa
    G L Drusano
    Ordway Research Institute, Albany, New York, USA
    Antimicrob Agents Chemother 56:231-42. 2012
  9. pmc Involvement of a novel efflux system in biofilm-specific resistance to antibiotics
    Li Zhang
    Department of Biochemistry, Microbiology and Immunology, 451 Smyth Road, University of Ottawa, Ottawa, ON, Canada K1N 8J2
    J Bacteriol 190:4447-52. 2008
  10. pmc Involvement of an ATP-dependent protease, PA0779/AsrA, in inducing heat shock in response to tobramycin in Pseudomonas aeruginosa
    Kristen N Kindrachuk
    Centre for Microbial Diseases and Immunity Research, Department of Microbiology and Immunology, University of British Columbia, No 232, 2259 Lower Mall, Lower Mall Research Station, Vancouver, British Columbia V6T 1Z4, Canada
    Antimicrob Agents Chemother 55:1874-82. 2011

Research Grants

Detail Information

Publications284 found, 100 shown here

  1. pmc Contributions of antibiotic penetration, oxygen limitation, and low metabolic activity to tolerance of Pseudomonas aeruginosa biofilms to ciprofloxacin and tobramycin
    Marshall C Walters
    Center for Biofilm Engineering, Department of Chemical Engineering, Montana State University Bozeman, Bozeman, Montana 59717 3980, USA
    Antimicrob Agents Chemother 47:317-23. 2003
    ..b>Tobramycin and ciprofloxacin penetrated biofilms but failed to effectively kill the bacteria...
  2. ncbi Synergistic antibacterial efficacy of early combination treatment with tobramycin and quorum-sensing inhibitors against Pseudomonas aeruginosa in an intraperitoneal foreign-body infection mouse model
    Louise D Christensen
    Department of International Health, Immunology and Microbiology, Faculty of Health Sciences, University of Copenhagen, DK 2200 Copenhagen, Denmark
    J Antimicrob Chemother 67:1198-206. 2012
    Quorum sensing (QS)-deficient Pseudomonas aeruginosa biofilms formed in vitro are more susceptible to tobramycin than QS-proficient P...
  3. pmc Fosfomycin/tobramycin for inhalation in patients with cystic fibrosis with pseudomonas airway infection
    Bruce C Trapnell
    Cincinnati Children s Hospital Medical Center, OH 45229, USA
    Am J Respir Crit Care Med 185:171-8. 2012
    Fosfomycin/tobramycin for inhalation (FTI), a unique, broad-spectrum antibiotic combination, may have therapeutic potential for patients with cystic fibrosis (CF).
  4. ncbi Aminoglycoside antibiotics induce bacterial biofilm formation
    Lucas R Hoffman
    Department of Pediatrics, University of Washington, Seattle, Washington 98195, USA
    Nature 436:1171-5. 2005
    ..cells with a mutation changing a predicted catalytic residue of Arr were defective in their biofilm response to tobramycin. Furthermore, tobramycin-inducible biofilm formation was inhibited by exogenous GTP, which is known to inhibit c-..
  5. ncbi Pseudomonas aeruginosa tolerance to tobramycin, hydrogen peroxide and polymorphonuclear leukocytes is quorum-sensing dependent
    Thomas Bjarnsholt
    Centre for Biomedical Microbiology, BioCentrum, Technical University of Denmark, DK 2800 Lyngby, Denmark
    Microbiology 151:373-83. 2005
    ..QS is blocked either by mutation or by administration of QS inhibitory drugs are sensitive to treatment with tobramycin and H2O2, and are readily phagocytosed by PMNs, in contrast to bacteria with functional QS systems...
  6. pmc Tobramycin and FDA-approved iron chelators eliminate Pseudomonas aeruginosa biofilms on cystic fibrosis cells
    Sophie Moreau-Marquis
    Department of Physiology, Dartmouth Medical School, Hanover, NH 03755, USA
    Am J Respir Cell Mol Biol 41:305-13. 2009
    ..investigated whether the FDA-approved iron chelators deferoxamine and deferasirox would enhance the ability of tobramycin, the primary antibiotic used to treat CF lung infections, to eliminate P. aeruginosa biofilms...
  7. ncbi Incidence and risk factors for multiple antibiotic-resistant Pseudomonas aeruginosa in cystic fibrosis
    Christian A Merlo
    The Johns Hopkins University School of Medicine, 1830 E Monument St Fifth Floor, Baltimore, MD 21205, USA
    Chest 132:562-8. 2007
    ..The main objective of the study was to estimate the incidence and identify risk factors for the acquisition of MARPA among individuals with CF...
  8. pmc Resistance emergence mechanism and mechanism of resistance suppression by tobramycin for cefepime for Pseudomonas aeruginosa
    G L Drusano
    Ordway Research Institute, Albany, New York, USA
    Antimicrob Agents Chemother 56:231-42. 2012
    ..Addition of a β-lactamase inhibitor suppressed resistance even with the stably derepressed isolate. Tobramycin combination studies demonstrated resistance suppression in both the wild-type and the stably derepressed ..
  9. pmc Involvement of a novel efflux system in biofilm-specific resistance to antibiotics
    Li Zhang
    Department of Biochemistry, Microbiology and Immunology, 451 Smyth Road, University of Ottawa, Ottawa, ON, Canada K1N 8J2
    J Bacteriol 190:4447-52. 2008
    ..aeruginosa PA14 background results in an increase in sensitivity to tobramycin, gentamicin, and ciprofloxacin, specifically when this mutant strain is growing in a biofilm...
  10. pmc Involvement of an ATP-dependent protease, PA0779/AsrA, in inducing heat shock in response to tobramycin in Pseudomonas aeruginosa
    Kristen N Kindrachuk
    Centre for Microbial Diseases and Immunity Research, Department of Microbiology and Immunology, University of British Columbia, No 232, 2259 Lower Mall, Lower Mall Research Station, Vancouver, British Columbia V6T 1Z4, Canada
    Antimicrob Agents Chemother 55:1874-82. 2011
    ..aeruginosa to lethal, inhibitory, and subinhibitory concentrations of tobramycin under aerobic and anaerobic conditions...
  11. ncbi Comparison of the next-generation aminoglycoside plazomicin to gentamicin, tobramycin and amikacin
    George G Zhanel
    Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Winnipeg, MB, Canada ca
    Expert Rev Anti Infect Ther 10:459-73. 2012
    ....
  12. ncbi Adaptive resistance to benzalkonium chloride, amikacin and tobramycin: the effect on susceptibility to other antimicrobials
    J A Joynson
    Kings College London, Sharnbrook, Bedfordshire, UK
    J Appl Microbiol 93:96-107. 2002
    ..strains of antimicrobial-resistant Pseudomonas aeruginosa via adaptation to benzalkonium chloride, amikacin and tobramycin and to then examine the incidence, or otherwise, of cross-resistance between antibiotics and between antibiotics ..
  13. pmc RpoS plays a central role in the SOS induction by sub-lethal aminoglycoside concentrations in Vibrio cholerae
    Zeynep Baharoglu
    Institut Pasteur, Unité Plasticité du Génome Bactérien, Département Génomes et Génétique, Paris, France
    PLoS Genet 9:e1003421. 2013
    ..cholerae and why they do not do so in E. coli. We found that when bacteria are grown with tobramycin at a concentration 100-fold below the MIC, intracellular reactive oxygen species strongly increase in V...
  14. ncbi EPR studies of free radicals decay and survival in gamma irradiated aminoglycoside antibiotics: sisomicin, tobramycin and paromomycin
    Sławomir Wilczyński
    Department of Biophysics, School of Pharmacy, Medical University of Silesia, Jednosci 8, 41 200 Sosnowiec, Poland
    Eur J Pharm Sci 45:251-62. 2012
    ..Free radicals in radiative sterilized sisomicin, tobramycin and paromomycin were studied by electron paramagnetic resonance (EPR) spectroscopy...
  15. pmc Tobramycin at subinhibitory concentration inhibits the RhlI/R quorum sensing system in a Pseudomonas aeruginosa environmental isolate
    Fedora Babic
    Department of Biochemistry and Molecular Biology, University of Zagreb, Croatia
    BMC Infect Dis 10:148. 2010
    ..A few studies have demonstrated the effect of tobramycin as a signal molecule on gene expression at the transcriptional level and its effect on bacterial physiology and ..
  16. ncbi Colistin-tobramycin combinations are superior to monotherapy concerning the killing of biofilm Pseudomonas aeruginosa
    Gloria Herrmann
    Institute of Medical Microbiology and Hygiene, Universitatsklinikum, University of Tubingen, Tubingen, Germany
    J Infect Dis 202:1585-92. 2010
    ..We tested the ability of colistin sulphate-tobramycin combinations and single antibiotics to kill P. aeruginosa biofilms.
  17. ncbi A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis
    M E Hodson
    Royal Brompton and Harefield NHS Trust, London, UK
    Eur Respir J 20:658-64. 2002
    ..The purpose of this trial was to assess the efficacy and safety of tobramycin nebuliser solution (TNS) and nebulised colistin in CF patients chronically infected with P. aeruginosa...
  18. pmc Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial
    Michael W Konstan
    Rainbow Babies and Children s Hospital, Case Western Reserve University School of Medicine, Cleveland, OH, USA
    J Cyst Fibros 10:54-61. 2011
    A light-porous-particle, dry-powder formulation of tobramycin was developed, using PulmoSphere® technology, to improve airway delivery efficiency, substantially reduce delivery time, and improve patient convenience and satisfaction...
  19. pmc Arginine or nitrate enhances antibiotic susceptibility of Pseudomonas aeruginosa in biofilms
    Giorgia Borriello
    Center for Biofilm Engineering and Department of Clinical Engineering, Montana State University Bozeman, 409 Cobleigh Hall, Bozeman, Montana 59717 3980, USA
    Antimicrob Agents Chemother 50:382-4. 2006
    Arginine enhanced the killing of Pseudomonas aeruginosa by ciprofloxacin and tobramycin under anaerobic, but not aerobic, growth conditions...
  20. ncbi Effects of loteprednol/tobramycin versus dexamethasone/tobramycin on intraocular pressure in healthy volunteers
    Edward J Holland
    Cincinnati Eye Institute and University of Cincinnati, Cincinnati, OH, USA
    Cornea 27:50-5. 2008
    To compare the steroid-induced intraocular pressure (IOP) and other ocular adverse effects of loteprednol etabonate 0.5% and tobramycin 0.3% ophthalmic suspension with those of dexamethasone 0.1% and tobramycin 0.3% ophthalmic suspension.
  21. ncbi Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis
    Richard B Moss
    Department of Pediatrics, Stanford University Medical Center, Palo Alto, CA 94304 5786, USA
    Chest 121:55-63. 2002
    ..To determine the effect of long-term suppression of Pseudomonas aeruginosa on lung function and other clinical end points in adolescent patients with cystic fibrosis (CF)...
  22. ncbi Effect of a single dose of tobramycin on systemic inflammatory response-induced acute kidney injury in a 6-hour porcine model
    Miklos Lipcsey
    Section of Anesthesiology and Intensive Care, Department of Surgical Sciences, Uppsala University, Uppsala, Sweden
    Crit Care Med 37:2782-90. 2009
    To evaluate whether the addition of tobramycin further compromises renal function in inflammatory response-induced acute kidney injury. Effective antibiotic treatment in septic shock is crucial for the outcome...
  23. pmc Differing effects of combination chemotherapy with meropenem and tobramycin on cell kill and suppression of resistance of wild-type Pseudomonas aeruginosa PAO1 and its isogenic MexAB efflux pump-overexpressed mutant
    G L Drusano
    Ordway Research Institute, 150 New Scotland Avenue, Albany, NY 12208, USA
    Antimicrob Agents Chemother 53:2266-73. 2009
    ..The suppression of resistance requires greater drug exposure. We examined the combination of meropenem and tobramycin for kill and resistance suppression (wild-type Pseudomonas aeruginosa PAO1 and its isogenic MexAB-overexpressed ..
  24. pmc Adherence with tobramycin inhaled solution and health care utilization
    Becky A Briesacher
    University of Massachusetts Medical School and Meyers Primary Care Institute, Worcester, MA, USA
    BMC Pulm Med 11:5. 2011
    Adherence with tobramycin inhalation solution (TIS) during routine cystic fibrosis (CF) care may differ from recommended guidelines and affect health care utilization.
  25. ncbi Long-term benefits of inhaled tobramycin in children with cystic fibrosis: first clinical observations from Poland
    Iwona Stelmach
    Department of Pediatrics and Allergy, N Copernicus Hospital, Lodz, Poland
    Respiration 75:178-81. 2008
    ..Respiratory disease is the major cause of mortality in cystic fibrosis (CF) patients and inhaled antibiotic therapy may contribute to the stabilization of lung function...
  26. pmc Neutrophil enhancement of Pseudomonas aeruginosa biofilm development: human F-actin and DNA as targets for therapy
    Quinn M Parks
    Department of Medicine, National Jewish Health, 1400 Jackson, Denver, CO, USA
    J Med Microbiol 58:492-502. 2009
    ..aeruginosa. Neutrophil F-actin represents a potential new therapeutic target for disruption of pathogenic biofilms...
  27. pmc Sputum tobramycin concentrations in cystic fibrosis patients with repeated administration of inhaled tobramycin
    Jennifer Ruddy
    Department of Pediatrics, Seattle Children s Hospital and University of Washington, Seattle, WA 98105, USA
    J Aerosol Med Pulm Drug Deliv 26:69-75. 2013
    Dosing of tobramycin solution for inhalation (TSI) in cystic fibrosis (CF) patients was based on single-dose pharmacokinetic studies...
  28. ncbi In vitro activities of the novel ceragenin CSA-13, alone or in combination with colistin, tobramycin, and ciprofloxacin, against Pseudomonas aeruginosa strains isolated from cystic fibrosis patients
    Cagla Bozkurt-Guzel
    Department of Pharmaceutical Microbiology, Faculty of Pharmacy, Istanbul University, Turkey
    Chemotherapy 57:505-10. 2011
    ..Among them CSA-13, a cationic steroid molecule, mimics the activity of naturally occurring antimicrobial peptides...
  29. pmc The effect of adding tobramycin to Simplex P cement on femoral stem micromotion as measured by radiostereometric analysis: a 2-year randomized controlled trial
    Eric Bohm
    Concordia Joint Replacement Group, Concordia Hip and Knee Institute, Winnipeg, Manitoba, Canada
    Acta Orthop 83:115-20. 2012
    ..However, no clinical studies have compared the performance of tobramycin-laden bone cement with that of standard bone cement (Simplex P).
  30. ncbi Variants of the gentamicin and tobramycin resistance plasmid pRAY are widely distributed in Acinetobacter
    Mohammad Hamidian
    School of Molecular Bioscience, The University of Sydney, NSW 2006, Australia
    J Antimicrob Chemother 67:2833-6. 2012
    To determine the cause of resistance to the aminoglycosides gentamicin and tobramycin in Acinetobacter isolates and the location of the resistance genes.
  31. ncbi Interaction between tobramycin and CSA-13 on clinical isolates of Pseudomonas aeruginosa in a model of young and mature biofilms
    Carole Nagant
    Laboratoire de Chimie Biologique et Médicale et de Microbiologie Pharmaceutique, Institut de Pharmacie, Universite Libre de Bruxelles, Brussels, Belgium
    Appl Microbiol Biotechnol 88:251-63. 2010
    ..eight strains of Pseudomonas aeruginosa (both reference and clinical strains) and compared with the response to tobramycin. In planktonic cultures, the minimal inhibitory and minimal bactericidal concentrations of CSA-13 and tobramycin ..
  32. ncbi Dose-dependent effects of topical tobramycin in an animal model of Pseudomonas sinusitis
    Marcelo B Antunes
    Department of Otorhinolaryngology, Division of Rhinology, University of Pennsylvania, Philadelphia 19104, USA
    Am J Rhinol 21:423-7. 2007
    ..Despite their popularity, there is limited data in the literature to support its use. This study is the first to examine the effects of topical tobramycin in an animal model of Pseudomonas sinusitis.
  33. ncbi Antimicrobial activity of fosfomycin and tobramycin in combination against cystic fibrosis pathogens under aerobic and anaerobic conditions
    Gerard McCaughey
    CF and Airways Microbiology Research Group, Queen s University Belfast, United Kingdom
    J Cyst Fibros 11:163-72. 2012
    ..There is a need for new antibiotics or combination of antibiotics that possess activity against increasingly resistant cystic fibrosis (CF) respiratory pathogens such as Pseudomonas aeruginosa and MRSA...
  34. pmc In vitro evaluation of tobramycin and aztreonam versus Pseudomonas aeruginosa biofilms on cystic fibrosis-derived human airway epithelial cells
    Qianru Yu
    Department of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Hanover, NH 03755, USA
    J Antimicrob Chemother 67:2673-81. 2012
    ..Here we investigated the effect of aztreonam alone or in combination with tobramycin on P. aeruginosa biofilms grown on CF airway epithelial cells.
  35. pmc 3-day treatment with azithromycin 1.5% eye drops versus 7-day treatment with tobramycin 0.3% for purulent bacterial conjunctivitis: multicentre, randomised and controlled trial in adults and children
    Isabelle Cochereau
    Service d Ophtalmologie, CHU d Angers, 4, rue Larrey, 49033 Angers, France
    Br J Ophthalmol 91:465-9. 2007
    To compare the efficacy and safety of Azyter, azithromycin 1.5% eye drops, for 3 days with tobramycin 0.3% for 7 days to treat purulent bacterial conjunctivitis.
  36. pmc Class 1 integron-associated tobramycin-gentamicin resistance in Campylobacter jejuni isolated from the broiler chicken house environment
    Margie D Lee
    Department of Medical Microbiology and Parasitology Athens Diagnostic Laboratory Department of Environmental Health Sciences, The University of Georgia, Athens, Georgia 30602, USA
    Antimicrob Agents Chemother 46:3660-4. 2002
    ..DNA sequencing demonstrated that all five isolates possessed the aminoglycoside resistance gene, aacA4...
  37. pmc Alginate overproduction affects Pseudomonas aeruginosa biofilm structure and function
    M Hentzer
    Department of Microbiology, Technical University of Denmark, 2800 Lyngby, Denmark
    J Bacteriol 183:5395-401. 2001
    ..strain exhibit a highly structured architecture and are significantly more resistant to the antibiotic tobramycin than a biofilm formed by an isogenic nonmucoid strain...
  38. ncbi Thiolated chitosans: development and in vitro evaluation of an oral tobramycin sulphate delivery system
    Juliane Hombach
    Institute of Pharmacy, Leopold Franzens University Innsbruck, Innrain 52, Josef Moller Haus, 6020 Innsbruck, Austria
    Eur J Pharm Sci 33:1-8. 2008
    The aim of the present study was to develop and evaluate an oral delivery system for tobramycin sulphate intended to improve the oral bioavailability...
  39. ncbi Comparison of the effects of macrolides, amoxicillin, ceftriaxone, doxycycline, tobramycin and fluoroquinolones, on the production of pneumolysin by Streptococcus pneumoniae in vitro
    R Anderson
    Medical Research Council MRC Unit for Inflammation and Immunity, Department of Immunology, Faculty of Health Sciences, University of Pretoria, and Tshwane Academic Division of the National Health Laboratory Service, South Africa
    J Antimicrob Chemother 60:1155-8. 2007
    ..azithromycin, clarithromycin, erythromycin, telithromycin, clindamycin, ciprofloxacin, moxifloxacin, tobramycin and doxycycline on pneumolysin production by a macrolide-susceptible strain and two macrolide-resistant strains [..
  40. ncbi Reduced mortality in cystic fibrosis patients treated with tobramycin inhalation solution
    Gregory S Sawicki
    Division of Respiratory Diseases, Children s Hospital Boston, Harvard Medical School, Boston, Massachusetts 02115, USA
    Pediatr Pulmonol 47:44-52. 2012
    Though tobramycin inhalation solution has been used for over a decade to improve lung function and reduce exacerbations in patients with cystic fibrosis (CF), its effects on mortality have not been well-described...
  41. ncbi Preparation and characterization of spray-dried tobramycin powders containing nanoparticles for pulmonary delivery
    Gabrielle Pilcer
    Laboratory of Pharmaceutics and Biopharmaceutics, Universite Libre de Bruxelles, Belgium
    Int J Pharm 365:162-9. 2009
    ..Spray-drying was applied in order to retrieve nanoparticles in dried-powder state from tobramycin nanosuspensions...
  42. ncbi Cationic amphiphiles increase activity of aminoglycoside antibiotic tobramycin in the presence of airway polyelectrolytes
    Kirstin R Purdy Drew
    Departments of Materials Science and Engineering, University of Illinois at Urbana Champaign, Urbana, Illinois 61801, USA
    J Am Chem Soc 131:486-93. 2009
    ..In this work, we use synchrotron small-angle X-ray scattering to investigate the interaction between tobramycin, an aminoglycoside antibiotic commonly administered to CF patients via inhalation, with DNA, which is found in ..
  43. ncbi A pilot study of the safety and efficacy of tobramycin solution for inhalation in patients with severe bronchiectasis
    Paul Scheinberg
    Atlanta Pulmonary Group, 5667 Peachtree Dunwoody Rd, Suite 350, Atlanta, GA 30350, USA
    Chest 127:1420-6. 2005
    To evaluate the efficacy and safety of tobramycin solution for inhalation (TSI) in patients with severe bronchiectasis.
  44. ncbi Serum tobramycin levels following delivery of tobramycin (Tobi) via eFlow advanced nebuliser in children with cystic fibrosis
    E L Guy
    Leeds Regional Paediatric Cystic Fibrosis Centre, St James s University Hospital, Leeds, LS9 7TF, United Kingdom
    J Cyst Fibros 9:292-5. 2010
    Safety and toxicity data for nebulised tobramycin are mainly derived from use of the Pari LC Plus nebuliser, yet many centres are now using advanced nebulisers, such as the eFlow.
  45. ncbi Local delivery of tobramycin from injectable biodegradable polyurethane scaffolds
    Andrea E Hafeman
    Department of Chemical Engineering, 2301 Vanderbilt Place, VU Station B 351604, Vanderbilt University, Nashville, TN 37235, USA
    J Biomater Sci Polym Ed 21:95-112. 2010
    ..In this study, injectable PUR scaffolds incorporating tobramycin were prepared by reactive liquid molding...
  46. ncbi NMR resonance assignments of an engineered neomycin-sensing riboswitch RNA bound to ribostamycin and tobramycin
    Sina R Schmidtke
    Institut für Molekulare Biowissenschaften, Johann Wolfgang Goethe Universität Frankfurt M, Max von Laue Str 9, 60438 Frankfurt, Germany
    Biomol NMR Assign 4:115-8. 2010
    ..the (1)H, (15)N, (13)C and partial (31)P chemical shift assignments for the minimal functional 27nt neomycin sensing riboswitch RNA in complex with the 4,5-linked neomycin analog ribostamycin and the 4,6-linked aminoglycoside tobramycin.
  47. ncbi Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis
    David E Geller
    Nemours Children s Clinic, Division of Pulmonology, Orlando, FL 32806, USA
    Chest 122:219-26. 2002
    To describe the pharmacokinetics and bioavailability of inhaled tobramycin (TOBI; Chiron Corporation; Seattle, WA), 300-mg dose, delivered by a nebulizer (PARI LC Plus; Pari Respiratory; Richmond, VA) and a compressor (Pulmo-Aide, model ..
  48. ncbi Comparison of the safety and efficacy of loteprednol 0.5%/tobramycin 0.3% with dexamethasone 0.1%/tobramycin 0.3% in the treatment of blepharokeratoconjunctivitis
    Eric M White
    Complete Family Vision Care, San Diego, CA, USA
    Curr Med Res Opin 24:287-96. 2008
    This study compared the safety and efficacy of loteprednol etabonate 0.5%/tobramycin 0.3% (LE/T; Zylet) with dexamethasone 0.1%/tobramycin 0...
  49. ncbi Pharmacokinetics and safety of tobramycin administered by the PARI eFlow rapid nebulizer in cystic fibrosis
    Dominique Hubert
    CRCM adultes, Hopital Cochin, Assistance Publique des Hopitaux de Paris, France
    J Cyst Fibros 8:332-7. 2009
    Nebulization times have been identified as an issue in patient compliance with tobramycin solution for inhalation (TSI) therapy in cystic fibrosis (CF).
  50. ncbi Treatment with tobramycin solution for inhalation reduces hospitalizations in young CF subjects with mild lung disease
    Timothy D Murphy
    Pulmonology Division, Department of Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
    Pediatr Pulmonol 38:314-20. 2004
    Our objective was to study the effect of tobramycin solution for inhalation (TSI; TOBI, Chiron Corp.) on lung function decline rate in 400 young persons with cystic fibrosis (CF) and mild lung disease...
  51. pmc In vitro analysis of tobramycin-treated Pseudomonas aeruginosa biofilms on cystic fibrosis-derived airway epithelial cells
    Gregory G Anderson
    Department of Microbiology and Immunology, Dartmouth Medical School, Hanover, New Hampshire 03755, USA
    Infect Immun 76:1423-33. 2008
    ..Treatment of P. aeruginosa biofilms with tobramycin reduced the virulence of the biofilms both by reducing bacterial numbers and by altering virulence gene ..
  52. pmc Targeting a bacterial stress response to enhance antibiotic action
    Samuel Lee
    Departments of Genome Sciences and Medicine and Microbiology, University of Washington, Seattle, WA 98195, USA
    Proc Natl Acad Sci U S A 106:14570-5. 2009
    ..in a screen of a comprehensive, defined transposon mutant library for functions whose inactivation increased tobramycin sensitivity...
  53. pmc Efficacy of the combination of tobramycin and a macrolide in an in vitro Pseudomonas aeruginosa mature biofilm model
    Marie Tre-Hardy
    Laboratoire de Chimie Biologique et Médicale et de Microbiologie Pharmaceutique, Institut de Pharmacie, Universite Libre de Bruxelles, CP 205 02, Bd du Triomphe, 1050 Brussels, Belgium
    Antimicrob Agents Chemother 54:4409-15. 2010
    ..The aim of this study was to compare the antimicrobial effects in vitro of the combinations tobramycin-clarithromycin and tobramycin-azithromycin against five P...
  54. pmc Development of an inhaled dry-powder formulation of tobramycin using PulmoSphere™ technology
    David E Geller
    Aerosol Research Laboratory and Cystic Fibrosis Center, Nemours Children s Clinic, Orlando, Florida
    J Aerosol Med Pulm Drug Deliv 24:175-82. 2011
    ..characteristics of PulmoSphere technology, focusing on the development of a dry powder formulation of tobramycin for the treatment of chronic pulmonary Pseudomonas aeruginosa (Pa) infection in CF patients...
  55. pmc Enhancement of antimicrobial activity against pseudomonas aeruginosa by coadministration of G10KHc and tobramycin
    Randal Eckert
    UCLA School of Dentistry, 10833 Le Conte Avenue, Los Angeles, CA 90095 1668, USA
    Antimicrob Agents Chemother 50:3833-8. 2006
    ..aeruginosa. G10KHc was found to be highly active (as active as tobramycin) against P. aeruginosa clinical isolates...
  56. ncbi Evaluation of clinical efficacy and safety of tobramycin/dexamethasone ophthalmic suspension 0.3%/0.05% compared to azithromycin ophthalmic solution 1% in the treatment of moderate to severe acute blepharitis/blepharoconjunctivitis
    Gail L Torkildsen
    Andover Eye Associates, Andover, MA 01810, USA
    Curr Med Res Opin 27:171-8. 2011
    To evaluate the clinical efficacy and safety of tobramycin/dexamethasone (TobraDex ST ; 'ST') ophthalmic suspension 0.3%/0...
  57. pmc Antibacterial activities of a fosfomycin/tobramycin combination: a novel inhaled antibiotic for bronchiectasis
    David L MacLeod
    Gilead Sciences, Inc, Seattle, WA 98121, USA
    J Antimicrob Chemother 64:829-36. 2009
    To compare the in vitro and in vivo activities of a 4:1 (w/w) fosfomycin/tobramycin combination (FTI) with those of fosfomycin and tobramycin alone against cystic fibrosis (CF) and non-CF bronchiectasis pathogens.
  58. ncbi Aminoglycoside-resistance mechanisms for cystic fibrosis Pseudomonas aeruginosa isolates are unchanged by long-term, intermittent, inhaled tobramycin treatment
    D L MacLeod
    Department of Research Biology, PathoGenesis Corp, Seattle, WA 98119, USA
    J Infect Dis 181:1180-4. 2000
    ..in Pseudomonas aeruginosa isolates from cystic fibrosis (CF) patients during a recent clinical trial of inhaled tobramycin. Impermeability, in which bacteria have reduced susceptibility to all aminoglycosides, was the predominant mode ..
  59. ncbi Isolation and characterization of the tobramycin biosynthetic gene cluster from Streptomyces tenebrarius
    Madan Kumar Kharel
    Institute of Biomolecule Reconstruction, Sun Moon University, 100, Kalsan ri, Tangjeong myeon, Asansi, Chungnam 336 708, South Korea
    FEMS Microbiol Lett 230:185-90. 2004
    The biosynthetic gene cluster for tobramycin, a 2-deoxystreptamine-containing aminoglycoside antibiotic, was isolated from Streptomyces tenebrarius ATCC 17920. A genomic library of S...
  60. ncbi Prevention of infection with tobramycin-containing bone cement or systemic cefazolin in an animal model
    M W Nijhof
    Department of Orthopaedics, G05 228, University Medical Center Utrecht, PO Box 85500, NL 3508 GA Utrecht, The Netherlands
    J Biomed Mater Res 52:709-15. 2000
    We investigated in an animal model the efficacy of tobramycin-containing bone cement and systemic cefazolin for infection prophylaxis...
  61. ncbi Comparison of in vivo intrinsic activity of cefepime and imipenem in a Pseudomonas aeruginosa rabbit endocarditis model: effect of combination with tobramycin simulating human serum pharmacokinetics
    Dominique Navas
    Laboratoire d Antibiologie UPRES EA 1156, UER de Medecine, 1 rue Gaston Veil, 44035 Nantes Cedex 01, France
    J Antimicrob Chemother 54:767-71. 2004
    ..Secondly, we studied the effect of combining therapy with tobramycin.
  62. pmc Endotoxin neutralization and anti-inflammatory effects of tobramycin and ceftazidime in porcine endotoxin shock
    Gunilla Goscinski
    Section of Infectious Diseases, Department of Medical Sciences, Uppsala University Hospital, Uppsala, Sweden
    Crit Care 8:R35-41. 2004
    ..The aim of the present study was to investigate whether the biological effects of endotoxin in a porcine model could be neutralized by tobramycin, and whether tobramycin or ceftazidime was able to modulate the inflammatory response.
  63. ncbi Transmucosal transport of tobramycin incorporated in solid lipid nanoparticles (SLN) after duodenal administration to rats. Part II--tissue distribution
    A Bargoni
    , Italy
    Pharmacol Res 43:497-502. 2001
    b>Tobramycin-loaded solid lipid nanoparticles (SLN) were prepared and administered by duodenal and intravenous (i.v...
  64. ncbi Synergism and postantibiotic effect of tobramycin and Melaleuca alternifolia (tea tree) oil against Staphylococcus aureus and Escherichia coli
    Manuela D'Arrigo
    Pharmaco Biological Department, University of Messina, Vill SS Annunziata 98168 Messina, Italy
    Phytomedicine 17:317-22. 2010
    ..We investigated the effectiveness in vitro of the association between tobramycin and tea tree oil (TTO) against Gram-positive and Gram-negative bacteria...
  65. ncbi Interaction of neomycin, tobramycin and amikacin with melanin in vitro in relation to aminoglycosides-induced ototoxicity
    E Buszman
    Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Medical University of Silesia, Sosnowiec, Poland
    Pharmazie 62:210-5. 2007
    ..The binding of neomycin, tobramycin and amikacin to model synthetic melanin was studied...
  66. ncbi Tobramycin Nebulizer Solution in severe COPD patients colonized with Pseudomonas aeruginosa: effects on bronchial inflammation
    Roberto Dal Negro
    UOC di Pneumologia, Ospedale Orlandi, Bussolengo, Verona, Italy
    Adv Ther 25:1019-30. 2008
    ..Inhaled Tobramycin Nebulizer Solution (TNS; a preservative-free formulation) is an effective therapy in chronic P aeruginosa ..
  67. pmc Tobramycin inhalation powder manufactured by improved process in cystic fibrosis: the randomized EDIT trial
    Ivanka Galeva
    Pediatric Clinic, UMHAT Alexandrovska, Sofia, Bulgaria
    Curr Med Res Opin 29:947-56. 2013
    b>Tobramycin inhalation powder (TIP) was reported to be effective in two Phase III studies in patients with cystic fibrosis (CF) chronically infected with Pseudomonas aeruginosa (Pa)...
  68. ncbi Efficacy of once-daily tobramycin monotherapy for acute pulmonary exacerbations of cystic fibrosis: a preliminary study
    V Master
    Department of Pulmonary Medicine, Adelaide Women s and Children s Hospital, North Adelaide, South Australia, Australia
    Pediatr Pulmonol 31:367-76. 2001
    Our objective was to compare the efficacy, safety, and microbiology of once-daily intravenous (IV) tobramycin with conventional 8-hourly tobramycin/ceftazidime IV therapy for acute Pseudomonas aeruginosa (PA) pulmonary exacerbations in ..
  69. ncbi Disposable versus reusable jet nebulizers for cystic fibrosis treatment with tobramycin
    Laurent Vecellio
    Aerodrug, Tours, F 37000, France
    J Cyst Fibros 10:86-92. 2011
    Jet nebulizers are commonly used to administer aerosolized tobramycin to CF patients. The aim of this study was to assess the performance of disposable jet nebulizers as an alternative to reusable nebulizers such as the Pari LC Plus.
  70. ncbi Evaluation of the in vivo efficacy of topical tobramycin against Pseudomonas sinonasal biofilms
    Alexander G Chiu
    Division of Rhinology, Department of Otorhinolaryngology Head and Neck Surgery, University of Pennsylvania, Philadelphia, PA, USA
    J Antimicrob Chemother 59:1130-4. 2007
    ..This is the first study to evaluate the effects of a topical antibiotic on Pseudomonas biofilms in an animal model of sinusitis...
  71. ncbi Formulation and characterization of lipid-coated tobramycin particles for dry powder inhalation
    Gabrielle Pilcer
    Laboratory of Pharmaceutics and Biopharmaceutics, Universite Libre de Bruxelles, Belgium
    Pharm Res 23:931-40. 2006
    ..This study was conducted to develop and evaluate the physicochemical and aerodynamic characteristics of lipid-coated dry powder formulations presenting particularly high lung deposition...
  72. ncbi Effect of oxygen limitation on the in vitro antimicrobial susceptibility of clinical isolates of Pseudomonas aeruginosa grown planktonically and as biofilms
    T R Field
    Clinical and Practice Research Group, School of Pharmacy, Queen s University Belfast, Medical Biology Centre, 97 Lisburn Road, Belfast, BT9 7BL, UK
    Eur J Clin Microbiol Infect Dis 24:677-87. 2005
    ..However, tobramycin was less effective at inhibiting planktonic bacterial growth under anaerobic conditions, with the MIC50 of ..
  73. ncbi Sputum antibiotic concentrations: implications for treatment of cystic fibrosis lung infection
    T F Moriarty
    The Clinical and Practice Research Group, School of Pharmacy, Queen s University Belfast, Belfast, UK
    Pediatr Pulmonol 42:1008-17. 2007
    ..The aim of this study was to determine whether PDIs associated with clinical effectiveness for ceftazidime and tobramycin were achieved at the site of infection in the lungs of cystic fibrosis (CF) patients following intravenous ..
  74. pmc Anti-inflammatory effects of tobramycin and a copper-tobramycin complex with superoxide dismutase-like activity
    M Gziut
    Institute of Biomedical and Biomolecular Sciences, School of Pharmacy and Biomedical Sciences, University of Portsmouth, Portsmouth, UK
    Br J Pharmacol 168:1165-81. 2013
    ..CF patients are routinely treated with systemic or inhaled tobramycin for airway infection with Pseudomonas aeruginosa...
  75. ncbi Aerosolized recombinant human lysozyme enhances the bactericidal effect of tobramycin in a hamster model of Pseudomonas aeruginosa-induced pneumonia
    Tapan Bhavsar
    Department of Pharmacy and Allied Health Sciences, St John s University, New York, New York, USA
    Exp Lung Res 37:536-41. 2011
    ..current investigation, our laboratory tested the hypothesis that aerosolized rhLZ can potentiate the effects of tobramycin (TBMN), thereby reducing the effective dose of this agent in the treatment of PA-induced pneumonia...
  76. pmc Comparison of the antimicrobial effects of chlorine, silver ion, and tobramycin on biofilm
    Jaeeun Kim
    School of Chemical and Biological Engineering, Seoul National University, Sillim dong, Gwanak Gu, Seoul, South Korea
    Antimicrob Agents Chemother 52:1446-53. 2008
    ..Three different antimicrobial agents (chlorine, silver, and tobramycin) and three different methods for the measurement of membrane integrity (plate counts, the measurement of ..
  77. pmc Novel genetic determinants of low-level aminoglycoside resistance in Pseudomonas aeruginosa
    Kristen N Schurek
    Centre for Microbial Diseases and Immunity Research, University of British Columbia, Room 232, 2259 Lower Mall, Lower Mall Research Station, Vancouver, British Columbia V6T1Z4, Canada
    Antimicrob Agents Chemother 52:4213-9. 2008
    ..library, consisting of approximately 5,800 mutants, was screened for twofold or greater increases in tobramycin resistance...
  78. ncbi Controlling Pseudomonas aeruginosa persister cells by weak electrochemical currents and synergistic effects with tobramycin
    Tagbo H R Niepa
    Department of Biomedical and Chemical Engineering, Syracuse University, Syracuse, NY 13244, USA
    Biomaterials 33:7356-65. 2012
    ..5 μg/mL tobramycin together using SS304 electrodes...
  79. pmc In vitro activities of quinolones, beta-lactams, tobramycin, and trimethoprim-sulfamethoxazole against nonfermentative gram-negative bacilli
    R J Fass
    Department of Internal Medicine, Ohio State University College of Medicine, Columbus 43210, USA
    Antimicrob Agents Chemother 40:1412-8. 1996
    ..ampicillin-sulbactam, piperacillin, piperacillin-tazobactam, ceftazidime, cefoperazone, ceftriaxone, imipenem, tobramycin, and trimethoprim-sulfamethoxazole (TMP-SMZ) were determined for 308 isolates, representing 13 species, by a ..
  80. pmc Fosfomycin enhances the active transport of tobramycin in Pseudomonas aeruginosa
    David L MacLeod
    Gilead Sciences, Inc, Seattle, Washington, USA
    Antimicrob Agents Chemother 56:1529-38. 2012
    ..In these studies, we demonstrate that fosfomycin synergistically enhances the activity of tobramycin in the presence of mucin...
  81. pmc Breakpoints for predicting Pseudomonas aeruginosa susceptibility to inhaled tobramycin in cystic fibrosis patients: use of high-range Etest strips
    María I Morosini
    Servicio de Microbiologia, Hospital Universitario Ramon y Cajal, Madrid, Spain
    J Clin Microbiol 43:4480-5. 2005
    Inhaled administration of tobramycin assures high concentrations in cystic fibrotic lungs, improving the therapeutic ratio over that of parenteral tobramycin levels, particularly against Pseudomonas aeruginosa...
  82. pmc Electrolytic generation of oxygen partially explains electrical enhancement of tobramycin efficacy against Pseudomonas aeruginosa biofilm
    P S Stewart
    Center for Biofilm Engineering, Montana State University Bozeman 59717 3980, USA
    Antimicrob Agents Chemother 43:292-6. 1999
    ..oxygen, hydrogen, and heat, in mediating electrical enhancement of killing of Pseudomonas aeruginosa biofilms by tobramycin (the bioelectric effect) was investigated...
  83. ncbi Serum cystatin C for the prediction of glomerular filtration rate with regard to the dose adjustment of amikacin, gentamicin, tobramycin, and vancomycin
    Jesus Hermida
    Laboratorio Central, Hospital Clinico Universitario, 15706 Santiago de Compostela, Spain
    Ther Drug Monit 28:326-31. 2006
    ..In 130 hospitalized patients who were administered amikacin, gentamicin, tobramycin, and vancomycin by intermittent intravenous infusion, we compared the predicted GFR values from the serum ..
  84. ncbi Optimization of capillary electrophoresis method with contactless conductivity detection for the analysis of tobramycin and its related substances
    Mohamed Nouri El-Attug
    Laboratory for Pharmaceutical Analysis, Faculteit Farmaceutische Wetenschappen, Katholieke Universiteit Leuven, O and N 2, PB 923, Herestraat 49, B 3000 Leuven, Belgium
    J Pharm Biomed Anal 58:49-57. 2012
    A method was validated and optimized to determine tobramycin (TOB) and its related substances. TOB is an aminoglycoside antibiotic which lacks a strong UV absorbing chromophore or fluorophore...
  85. pmc Efficacy of liposomal bismuth-ethanedithiol-loaded tobramycin after intratracheal administration in rats with pulmonary Pseudomonas aeruginosa infection
    Moayad Alhariri
    Novel Drug and Vaccine Delivery Systems Facility, Department of Chemistry and Biochemistry, Laurentian University, Sudbury, ON, Canada
    Antimicrob Agents Chemother 57:569-78. 2013
    ..as well as the in vivo antimicrobial activity of bismuth-ethanedithiol incorporated into a liposome-loaded tobramycin formulation (LipoBiEDT-TOB) administered to rats chronically infected with P. aeruginosa...
  86. ncbi Outpatient treatment of Pseudomonas aeruginosa bronchial colonization with long-term inhaled colistin, tobramycin, or both in adults without cystic fibrosis
    David Berlana
    Departments of Pharmacy, Bellvitge University Hospital, Barcelona, Spain
    Pharmacotherapy 31:146-57. 2011
    ..outcomes in adults without cystic fibrosis who had Pseudomonas aeruginosa bronchial colonization and were receiving inhaled colistin or colistin plus tobramycin with those who were receiving inhaled tobramycin as outpatient treatment.
  87. pmc Safety and effectiveness of colistin compared with tobramycin for multi-drug resistant Acinetobacter baumannii infections
    Ronald Gounden
    Department of Medicine, Division of Clinical Pharmacology, University of Cape Town, Cape Town, South Africa
    BMC Infect Dis 9:26. 2009
    ..Nosocomial infections due to multi-drug resistant Acinetobacter baumannii are often treated with colistin, but there are few data comparing its safety and efficacy with other antimicrobials...
  88. ncbi Ketorolac plus tobramycin/dexamethasone versus tobramycin/dexamethasone after uneventful phacoemulsification surgery: a randomized controlled trial
    Irini P Chatziralli
    Department of Ophthalmology, Veroia General Hospital, 28 Papanastasiou Street, Veroia, Greece
    Ophthalmologica 225:89-94. 2011
    ....
  89. ncbi Attenuation of Pseudomonas aeruginosa virulence factors and biofilms by co-encapsulation of bismuth-ethanedithiol with tobramycin in liposomes
    Misagh Alipour
    The Novel Drug and Vaccine Delivery Systems Facility, Department of Chemistry and Biochemistry, Laurentian University, Sudbury, Ontario, P3E 2C6, Canada
    J Antimicrob Chemother 65:684-93. 2010
    This study examined the activities of tobramycin and bismuth against quorum sensing, virulence factors and biofilms of Pseudomonas aeruginosa by co-encapsulating the agents in liposomes in order to achieve greater delivery of the agents.
  90. ncbi Resistance to tobramycin and colistin in isolates of Pseudomonas aeruginosa from chronically colonized patients with cystic fibrosis under antimicrobial treatment
    Giuseppe Valenza
    Institute of Hygiene and Microbiology, University of Wurzburg, Wurzburg, Germany
    Scand J Infect Dis 42:885-9. 2010
    b>Tobramycin and colistin represent 2 standard antimicrobial agents in the treatment of cystic fibrosis (CF) patients who are chronically colonized with Pseudomonas aeruginosa...
  91. ncbi Prophylaxis of catheter-related bacteremia using tissue plasminogen activator-tobramycin locks
    Ali Mirza Onder
    West Virginia University, WVU HSC, Morgantown, 26506 9214, USA
    Pediatr Nephrol 24:2233-43. 2009
    This retrospective study was designed to investigate the effectiveness of tissue plasminogen activator-tobramycin antibiotic lock solutions (TPA/tobra ABLs) for prophylaxis of catheter-related bacteremia (CRB) in high-risk children on ..
  92. ncbi Open follow-up study of tobramycin nebuliser solution and colistin in patients with cystic fibrosis
    David Adeboyeku
    Department of Cystic Fibrosis, Royal Brompton Hospital, Sydney Street, London, UK
    J Cyst Fibros 5:261-3. 2006
    A previous study of tobramycin nebuliser solution (TNS) compared with colistin [C] in cystic fibrosis (CF) patients, chronically infected with pseudomonas, showed benefit for the TNS treated patients over one treatment cycle only...
  93. ncbi Pharmacoscintigraphic and pharmacokinetic evaluation of tobramycin DPI formulations in cystic fibrosis patients
    Gabrielle Pilcer
    Laboratory of Pharmaceutics and Biopharmaceutics, Universite Libre de Bruxelles, Brussels, Belgium
    Eur J Pharm Biopharm 68:413-21. 2008
    b>Tobramycin dry powder formulations were evaluated by gamma scintigraphy and pharmacokinetic methods...
  94. ncbi Effects of antibiotics on morphologic characteristics and migration of canine corneal epithelial cells in tissue culture
    D V Hendrix
    Department of Small Animal Clinical Sciences, College of Veterinary Medicine, University of Tennessee, Knoxville 37901, USA
    Am J Vet Res 62:1664-9. 2001
    ..Cells treated with tobramycin and chloramphenicol grew similarly to control cells...
  95. ncbi In vitro efficacy of an ophthalmic drug combination against corneal pathogens of horses
    Nicole C Scotty
    University of Florida Veterinary Medical Center, Department of Small Animal Clinical Sciences, College of Veterinary Medicine, University of Florida, Gainesville, FL 32608, USA
    Am J Vet Res 69:101-7. 2008
    ..To evaluate the in vitro efficacy of an ophthalmic drug combination against common corneal pathogens of horses...
  96. ncbi In-vivo impact of the MexXY efflux system on aminoglycoside efficacy in an experimental model of Pseudomonas aeruginosa pneumonia treated with tobramycin
    B Martha
    Division of Infectious Diseases, Hopital du Bocage, University Hospital, 21000 Dijon, France
    Clin Microbiol Infect 12:426-32. 2006
    ..MexXY efflux pump was investigated in vivo in an experimental model of PAP in rabbits treated with intravenous tobramycin. Three strains were used to induce PAP in rabbits: PAO1 (wild-type strain; MIC 1 mg/L), mutant 11B (mexX::Tn501; ..
  97. ncbi Pharmacokinetic studies on tobramycin in horses
    H Hubenov
    Department of Surgery, Faculty of Veterinary Medicine, Trakia University, Stara Zagora, Bulgaria
    J Vet Pharmacol Ther 30:353-7. 2007
    The objective of the study was to evaluate the pharmacokinetics of tobramycin in plasma and urine in the horse (n = 7) after intravenous administration of a dose of 4 mg/kg b.w...
  98. ncbi Ocular distribution, bactericidal activity and settling characteristics of TobraDex ST ophthalmic suspension compared with TobraDex ophthalmic suspension
    Stephen V Scoper
    Virginia Eye Consultants, Norfolk, Virginia, USA
    Adv Ther 25:77-88. 2008
    TobraDex ophthalmic suspension (tobramycin 0.3%, dexamethasone 0.1%; Alcon Laboratories Inc, Fort Worth, Tex) is frequently used for inflammatory ocular conditions where a risk of bacterial ocular infection exists...
  99. ncbi Influence of gentamicin and tobramycin on binary biofilm formation by co-cultures of Burkholderia cepacia and Pseudomonas aeruginosa
    Amal G Al-Bakri
    School of Pharmacy and Pharmaceutical Sciences, University of Manchester, Oxford Road, Manchester M13 9PL, England, UK
    J Basic Microbiol 45:392-6. 2005
    ..Pans, containing established biofilms, were swapped between CDFFs. Biofilms were treated either for 5 days with tobramycin (0.3 mg/ml) prior to pan-swapping, or with gentamicin (1 mg/ml) immediately following pan-swapping...
  100. ncbi In vitro postantibiotic effect and postantibiotic leukocyte enhancement of tobramycin
    A Novelli
    Department of Pharmacology, University of Florence, Italy
    J Chemother 7:355-62. 1995
    The occurrence of a postantibiotic effect (PAE) and postantibiotic leukocyte enhancement (PALE) of tobramycin, a natural aminoglycoside clinically used since the early 1970s, has been investigated in comparison to gentamicin on recent ..
  101. ncbi Simple and sensitive method for quantification of low tobramycin concentrations in human plasma using HPLC-MS/MS
    Milly E Attema-de Jonge
    Department of Pharmacy, Onze Lieve Vrouwe Gasthuis, Oosterpark 9, 1091 AC Amsterdam, The Netherlands
    J Chromatogr B Analyt Technol Biomed Life Sci 862:257-62. 2008
    After oral administration of tobramycin, as part of selective decontamination of the digestive tract (SDD) in critically ill patients, absorption of tobramycin from the gut into the blood may take place...

Research Grants54

  1. Use of Gallium to Prevent Pseudomonas Biofilm Formation
    Bradley Britigan; Fiscal Year: 2005
    ..aeruginosa biofilm formation and enhances its susceptibility to tobramycin. Gallium (Ca), a group IliA transition metal disrupts the Fe metabolism of many cell types...
  2. Antibiotic-mediated Adaptation of Pseudomonas aeruginosa
    LUCAS HOFFMAN; Fiscal Year: 2007
    ..aeruginosa responds specifically to subinhibitory concentrations of the antibiotic tobramycin with increased biofilm formation. Tobramycin-induced biofilms are more resistant to further antibiotic challenge...
  3. Photodynamic Therapy of Localized Infections
    Michael R Hamblin; Fiscal Year: 2013
    ..Preliminary data has shown that a sub-therapeutic regimen of tobramycin can synergistically combine with a PDT regimen mediated by a fullerene and white light to save mice from dying ..
  4. Aminoglycoside potentiators for P. aeruginosa therapy
    Donald T Moir; Fiscal Year: 2013
    ..While P. aeruginosa exhibits an alarming variety of intrinsic drug resistances, aminoglycosides (AMGs) such as tobramycin and amikacin, are still effective in treating diseases caused by this pathogen, including CF and ventilator- ..
  5. Anti-biofilm agents for treating pulmonary infection in Cystic Fibrosis patients
    LAURA MICHELLE GUOGAS; Fiscal Year: 2011
    ..aeruginosa at low-micromolar concentrations and 2) working synergistically with tobramycin to stop growth of P. aeruginosa in broth culture...
  6. OPTIMIZE - CCC - Lead Application
    Bonnie W Ramsey; Fiscal Year: 2013
    ..children with CF and new onset Pa (the EPIC trial) demonstrated that an anti-pseudomonal treatment strategy with tobramycin inhalation solution (TIS) given only when respiratory cultures are positive for Pa leads to comparable clinical ..
  7. OPTIMIZE - DCC
    Nicole Mayer Hamblett; Fiscal Year: 2013
    ..children with CF and new onset Pa (the EPIC trial) demonstrated that an anti-pseudomonal treatment strategy with tobramycin inhalation solution (TIS) given only when respiratory cultures are positive for Pa leads to comparable clinical ..
  8. Antibacterial Perfluorocarbon Ventilation to Treat Severe Respiratory Infections
    KEITH ELLIOT COOK; Fiscal Year: 2013
    ..We will then compare treatment of this infection with either 1) inhaled tobramycin alone, 2) perfluorocarbon ventilation followed by inhaled tobramycin, 3) perfluorocarbon ventilation with ..
  9. Enzymatic Therapies for Cystic Fibrosis Biofilms
    PHILLIP J BRUMM; Fiscal Year: 2011
    ..The optimal enzyme mixture will then be tested in combination with Tobramycin to test the hypothesis that enzymatic degradation of the P...
  10. Pharmacodynamic modeling of antibiotics on cystic fibrosis P. aeruginosa biofilms
    Katherine Y Yang; Fiscal Year: 2013
    ..In Aim 2, this model will be used to determine the biofilm PD targets of meropenem and tobramycin, administered alone and in combination, on a unique collection of genetically identical P...
  11. Translational Research Center for Expedite Novel Therapies in Cystic Fibrosis
    Bonnie W Ramsey; Fiscal Year: 2013
    ..history of excellence in CF related translational research as evidenced by successful development of inhaled tobramycin (TOBI(r)) and leadership in the CFF supported Therapeutics Development Network...
  12. Mechanistic Studies of Deoxy Sugar Biosynthesis
    Hung wen Liu; Fiscal Year: 2013
    ..targeting the biosynthetic pathways and enzymes for the production of methylthiolincosamide, desosamine, tobramycin, oxetanocin, and the carbohydrate appendages of gentamicin...
  13. NEW DRUGS FOR RESISTANT DISEASE FROM CI/MS STUDIES
    VERONICA BIERBAUM; Fiscal Year: 2000
    ..The aminoglycoside antibiotics such as gentamycin, tobramycin, neomycin, and amikacin will also be examined in conjunction with resistant and sensitive strains of E...
  14. Topical negative pressure dressings for the prevention of chronic wound biofilm
    GUY ORGAMBIDE; Fiscal Year: 2009
    ..We have identified tobramycin (strongly active against Pseudomonas aeruginosa and Gram positive bacteria) as the clinically preferred agent ..
  15. Respirable ciprofloxacin aerosol for inhaled anthrax
    Brooks Hybertson; Fiscal Year: 2004
    ..Although several water-soluble antibiotics, including tobramycin, have been formulated for pulmonary delivery as inhaled aerosols, respirable particles of highly lipophilic ..
  16. OXY-RADICALS IN GENTAMICIN AND OTHER TOXIC NEPHROPATHIES
    Patrick Walker; Fiscal Year: 1992
    ..g. other aminoglycoside-induced (Tobramycin, etc.), endotoxin-induced, glycerol-induced, and uranyl nitrate-induced ARF.
  17. INHALED TOBRAMYCIN IN YOUNG CYSTIC FIBROSIS PATIENTS
    Bonnie Ramsey; Fiscal Year: 2003
    ..of this proposal is to determine the short-term microbiologic efficacy and safety of an inhaled antibiotic, tobramycin solution for inhalation (TOBI), in infants and young children with cystic fibrosis (CF) and documented ..
  18. FLUORESCENT LABELING OF NUCLEIC ACIDS
    LARRY MCLAUGHLIN; Fiscal Year: 2001
    ..We will examine the structure stabilizing abilities of Tobramycin, Neomycin B, and various analogues constructed on a Neamine core disaccharide...
  19. Undermining aminoglycoside resistance in Pseudomonas aeruginosa
    Colin Manoil; Fiscal Year: 2009
    ..aeruginosa. We have found that mutations inactivating the regulator lead to enhanced aminoglycoside (tobramycin) sensitivity in a number of isolates, effectively undermining intrinsic resistance to the antibiotic...
  20. RNA APTAMER COMPLEXES--STRUCTURES AND INTERACTIONS
    Dinshaw Patel; Fiscal Year: 1999
    ..on RNA aptamers complexed to flavin mononucleotide, adenosine triphosphate and the aminoglycoside antibiotic tobramycin that exhibit extremely well resolved spectra and are amenable to structural characterization in solution...
  21. FORMULATION FOR IMPROVED OPHTHALMIC ANTIBIOTIC EFFICACY
    S Chandrasekaran; Fiscal Year: 1993
    ..During this phase of the investigation, a tobramycin formulation (TobraSite) using InSite's proprietary insoluble polymer vehicle (DuraSiteTM) was developed that had ..
  22. INHALED AZTREONAM FOR CYSTIC FIBROSIS
    Alan Montgomery; Fiscal Year: 2006
    ..the ability of inhaled aztreonam (AI) to maintain or improve the clinical status following a 28-day course of tobramycin solution for inhalation...
  23. FORMULATION FOR IMPROVED OPHTHALMIC ANTIBIOTIC EFFICACY
    S Chandrasekaran; Fiscal Year: 1990
    ..other vehicle excipients to form a sustained release formulation compatible with a broad spectrum drug such as tobramycin, an anti-infective drug already approved for use in the eye...
  24. MENTORED PATIENT ORIENTED RESEARCH CAREER DEVELOPMENT AW
    Margaret Rosenfeld; Fiscal Year: 2004
    ..The initial development of proposed model will be conducted utilizing aerosolized tobramycin, which has been shown to be safe and effective in the treatment of CF patients over six years of age and was ..
  25. Development of Etched Modified Capillaries
    JOSEPH PESEK; Fiscal Year: 2002
    ..Microsolv Corporation will undertake a marketing plan to distribute the products for use by companies working in the targeted application areas. ..
  26. MECHANISMS OF CELL INJURY IN BURN COMPLICATED BY SEPSIS
    Deborah Carlson; Fiscal Year: 2006
    ..The proposed work focuses on five specific aims to increase our understanding of the cellular events involved in burn and sepsis-related myocardial injury. ..
  27. Susceptibility Testing, Treatment Choices, and Outcomes of MDR-GNB Infections
    Lisa Saiman; Fiscal Year: 2009
    ..Carefully conducted observational studies and clinically relevant in vitro antimicrobial susceptibility testing, hold the greatest promise to improve the treatment of patients infected with mutidrug-resistant organisms. ..
  28. Open Tubular Capillary Electrochromatography/Mass Spectroscopy
    JOSEPH PESEK; Fiscal Year: 2007
    ..This project focuses on providing a means for the analysis of complex samples found in clinical, biological and pharmaceutical applications. [unreadable] [unreadable] [unreadable]..
  29. REPLICATION OF OXIDATIVE LESIONS BY BYPASS POLYMERASES
    Dinshaw Patel; Fiscal Year: 2009
    ..abstract_text> ..
  30. Environmental Effects on Lung Function in Cystic Fibrosis Patients
    Christopher Goss; Fiscal Year: 2008
    ..Our proposal will also enhance our understanding of lung growth in CF and represents the initial phase of a program to understand environmental effects on CF lung disease. [unreadable] [unreadable] [unreadable]..
  31. siRNA-Mediated Silencing of Viral Infection & Viral Suppressors of RNA Silencing
    Dinshaw J Patel; Fiscal Year: 2010
    ..abstract_text> ..
  32. MOLECULAR BASIS OF GLYCOSPHINGOLIPID BINDING SPECIFICITY
    Dinshaw J Patel; Fiscal Year: 2010
    ....
  33. ANTITUMOR DRUG DNA AND DNA APTAMER COMPLEXES IN SOLUTION
    Dinshaw Patel; Fiscal Year: 2002
    ....
  34. PROTEIN-RNA RECOGNITION IN NEURODEGENERATIVE SYNDROMES
    Dinshaw Patel; Fiscal Year: 2008
    ..abstract_text> ..
  35. Burkholderia sp: Identification of major clonal lineages
    John LiPuma; Fiscal Year: 2004
    ..mallei and B. pseudomallei. ..
  36. Regulation of CFTR by adenosine, A2 receptors, and PLA2
    John Clancy; Fiscal Year: 2004
    ..The experiments outlined also identify a new way to regulate CFTR, and therefore may help define new therapeutic targets in the disease. ..
  37. GM-CSF & Alveolar Macrophage Antiviral Lung Defense
    Bruce Trapnell; Fiscal Year: 2004
    ..abstract_text> ..
  38. Conference--Pulmonary Alveolar Proteinosis Research
    Bruce Trapnell; Fiscal Year: 2004
    ..Recent progress in PAP research represents a paradigm of the intersection of basic science, clinical medicine and translational research, which has taken this disease from obscurity to clarity in a decade. ..
  39. Antibiotic Susceptibility of Bacteria in Biofilms
    Philip Stewart; Fiscal Year: 2005
    ..This project will afford a rich interdisciplinary training experience for the three participating graduate students. ..
  40. Host-Pathogen Interactions in Cystic Fibrosis
    SAMUEL MOSKOWITZ; Fiscal Year: 2005
    ..Identifying innate immune genes as modifiers of the CF lung phenotype may suggest new avenues for treating the inflammatory consequences of CF airway infection. ..
  41. Regulation of Alveolar Macrophage Phagocytosis
    Bruce Trapnell; Fiscal Year: 2006
    ..1, and Hck/SFKs in AMs. Results of this research are expected to help establish the feasibility of the therapeutic use of GM-CSF in the treatment of lung infections by a wide variety of microbial pathogens. ..
  42. Influence of ENaC Regulators on CF Lung Severity
    SAMUEL MOSKOWITZ; Fiscal Year: 2006
    ..Identifying ENaC regulatory genes as modifiers of the CF lung phenotype would provide important insights into disease pathogenesis and define novel targets for therapeutic intervention. ..
  43. Pulmonary Alveolar Proteinosis Research Conference
    Bruce Trapnell; Fiscal Year: 2005
    ..This conference will provide a forum where thought leaders focused on the molecular and cellular basis or clinical management of PAP will present cutting edge research, integrate concepts, and chart innovative research directions. ..
  44. Beacon Aptamers for the Detection of Small Molecules
    Daniel Morse; Fiscal Year: 2006
    ..The selection strategy will be tested by using the antibiotic tobramycin as the target...
  45. Role of Virus and Genetic Susceptibility in Otitis Media
    Cuneyt Alper; Fiscal Year: 2006
    ..These results will be used in the design of future studies that prevent OM by moderating vURI pathogenesis. [unreadable] [unreadable]..
  46. AAT Deficiency & Liver Diseases Caused by Proteins
    Bruce Trapnell; Fiscal Year: 2006
    ..unreadable] [unreadable]..
  47. Fourth Annual International Pulmonary Alveolar Proteinosis Research Conference
    Bruce Trapnell; Fiscal Year: 2006
    ..unreadable] [unreadable] [unreadable] [unreadable]..
  48. Biofilm growth and detachment of an oral pathogen
    Jeffrey Kaplan; Fiscal Year: 2007
    ..abstract_text> ..
  49. Quality of Life in patients with severe Cystic Fibrosis
    Christopher Goss; Fiscal Year: 2007
    ....
  50. RNA REGULATORY DOMAINS: FOLDING, RECOGNITION & CATALYSIS
    Dinshaw Patel; Fiscal Year: 2008
    ....
  51. Airway Epithelial Adaptation to Infectious Stimuli
    Scott Randell; Fiscal Year: 2008
    ..A greater understanding of airway epithelial adaptation, and its functional outcome, provides a logical basis for the design of novel anti-inflammatory therapies. ..
  52. IDENTIFICATION OF AIRWAY EPITHELIAL STEM CELLS
    Scott Randell; Fiscal Year: 2004
    ..abstract_text> ..